RLFT.F Stock Overview
A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2.86 |
| 52 Week High | CHF 7.66 |
| 52 Week Low | CHF 1.10 |
| Beta | -15.3 |
| 1 Month Change | -20.78% |
| 3 Month Change | -37.24% |
| 1 Year Change | 78.97% |
| 3 Year Change | -89.82% |
| 5 Year Change | n/a |
| Change since IPO | -82.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| RLFT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.5% | -1.4% | 0.6% |
| 1Y | 79.0% | -6.8% | 7.9% |
Return vs Industry: RLFT.F exceeded the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: RLFT.F exceeded the US Market which returned 7.9% over the past year.
Price Volatility
| RLFT.F volatility | |
|---|---|
| RLFT.F Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RLFT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RLFT.F's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 49 | n/a | www.relieftherapeutics.com |
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
| RLFT.F fundamental statistics | |
|---|---|
| Market cap | US$33.65m |
| Earnings (TTM) | -US$111.16m |
| Revenue (TTM) | US$6.83m |
4.9x
P/S Ratio-0.3x
P/E RatioIs RLFT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLFT.F income statement (TTM) | |
|---|---|
| Revenue | CHF 6.03m |
| Cost of Revenue | CHF 1.92m |
| Gross Profit | CHF 4.11m |
| Other Expenses | CHF 102.29m |
| Earnings | -CHF 98.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 10, 2025
| Earnings per share (EPS) | -7.83 |
| Gross Margin | 68.18% |
| Net Profit Margin | -1,627.40% |
| Debt/Equity Ratio | 3.3% |
How did RLFT.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 18:11 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandre Müller | Research Dynamics |
| Bob Pooler | ValuationLAB AG |